MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
02 November 2023 - 6:00PM
Business Wire
- Poster 1 presents Early Access Program (EAP) data for 111
patients with acute Graft-vs-Host Disease (aGvHD) treated with
MaaT013.
- Poster 2 details the Phase 2b randomized, double-blinded study
evaluating MaaT033 to enhance overall survival in allogenic
hematopoietic cell transplantation patients.
- For the seventh consecutive year, MaaT Pharma's abstracts have
been selected for presentation at the ASH Annual Meeting,
reinforcing the Company's leadership in
microbiome/hematology-oncology.
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a
clinical-stage biotechnology company and a leader in the
development of Microbiome Ecosystem TherapiesTM (MET) dedicated to
enhancing survival for patients with cancer, announced today
that extended results from its Early Access Program of MaaT013 in
111 patients (additional 30 patients included in the Program
compared to last year) with aGvHD and the design of its Phase 2b
study evaluating MaaT033 in improving overall survival in patients
undergoing allogenic hematopoietic cell transplantation (allo-HSCT)
have been selected for poster presentations at the 65th American
Society of Hematology (ASH) Annual Meeting held from December 9-12,
2023, in San Diego, California, USA. This is the seventh year in a
row that the Company’s clinical data and activities have been
selected for a presentation at the ASH Annual Meeting, the
world-leading event in malignant and non-malignant hematology,
demonstrating the ongoing interest from clinicians for microbiome
modulation approaches in the hemato-oncology field.
In line with the conference embargo policy, MaaT Pharma will
detail the presented results through a press release on Monday,
December 11th, 2023. The Company will also host an investor webcast
on Monday, December 18th, 2023, at 6:00pm CET (further details to
follow).
The EAP results include data from 111 patients with
steroid-resistant or steroid-dependent aGvHD treated with MaaT013,
previously unresponsive to 1-6 lines of therapy. MaaT013 is
currently being evaluated in a pivotal Phase 3 trial (n=75) for
corticosteroid- and ruxolitinib-refractory gastrointestinal aGvHD.
The Company shared the positive review by DSMB in October 2023 for
this Phase 3 trial, including a favorable benefit/risk ratio, with
a good safety profile and positive preliminary efficacy results. As
of today, over 170 patients have been safely treated with MaaT013
in Europe in clinical trials and the EAP.
The Company provides an update on MaaT033, an oral ecosystem
microbiome capsule for adjunctive therapy, and will share the
design of the Phase 2b trial, the largest randomized clinical trial
(RCT) study for a microbiome therapy in hemato-oncology to date
with the enrollment of 387 patients, investigating the efficacy of
MaaT033 in improving overall survival for patients receiving
allo-HSCT.
Poster Presentations:
MaaT013
- Title: Pooled Fecal Allogenic Microbiotherapy for Refractory
Gastrointestinal Acute Graft-Versus-Host Disease: Results from
Early Access Program in Europe
- Poster number: 3553
- Presenter: Professor Florent Malard, hematology professor at
the Saint-Antoine Hospital and Sorbonne University
- Session: 722. Allogeneic Transplantation: Acute and Chronic
GVHD, Immune Reconstitution: Poster II
- Session Date/Time: Sunday, December 10, 2023: 6:00pm -8:00pm
EST
- Location: San Diego Convention Center, Halls G-H
MaaT033
- Title: A Multicentre, Randomized, Double-Blinded, Phase 2b
Study Evaluating the Efficacy and Safety of MaaT033, an Oral,
Pooled Microbiome Ecosystem Therapy in Patients Undergoing
Allogenic Hematopoietic Cell Transplantation to Improve Overall
Survival: The Phoebus Trial
- Poster number: 4947
- Presenter: Professor Florent Malard, hematology professor at
the Saint-Antoine Hospital and Sorbonne University
- Session: 722. Allogeneic Transplantation: Acute and Chronic
GVHD, Immune Reconstitution: Poster III
- Session Date/Time: Monday, December 11, 2023: 6:00pm -8:00pm
EST
- Location: San Diego Convention Center, Halls G-H
Upcoming scientific conference participations
- November 1-5, 2023 – 38th Society for Immunotherapy of Cancer
(SITC) Annual Meeting - Posters presentations
- November 15-17, 2023 – 22nd Société Francophone de Greffe de
Moelle et de Thérapie Cellulaire (SFGM-TC) Congress - Booth
#12
- December 9-12, 2023 - 65th American Society of Hematology (ASH)
Annual Meeting- Posters presentations
About MaaT Pharma
MaaT Pharma, a leading clinical-stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma initiated an
open-label, single-arm Phase 3 clinical trial in patients with
acute GvHD, building on the positive results of its Phase 2
proof-of-concept. Its powerful discovery and analysis platform,
gutPrint®, enables the identification of novel disease targets,
evaluation of drug candidates, and identification of biomarkers for
microbiome-related conditions. The company’s Microbiome Ecosystem
Therapies are produced through a standardized cGMP manufacturing
and quality control process to safely deliver the full diversity of
the microbiome in liquid and oral formulations. MaaT Pharma
benefits from the commitment of world-leading scientists and
established relationships with regulators to support the
integration of the use of microbiome therapies in clinical
practice. MaaT Pharma is listed on Euronext Paris (ticker:
MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by or including words such as “target,” “believe,”
“expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231102989593/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50
invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com
Trophic Communications – Corporate Communications Jacob
VERGHESE or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Maat Pharma (EU:MAAT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024